documents
Data license: Public Domain (U.S. Government data) · Data source: Federal Register API & Regulations.gov API
12 rows where docket_id = "FDA-2020-D-1136" and posted_year = 2021 sorted by posted_date descending
This data as json, CSV (advanced)
Suggested facets: title, subtype, posted_month, comment_end_date, open_for_comment, posted_date (date), comment_start_date (date), comment_end_date (date), last_modified (date)
| id | agency_id | docket_id | title | document_type | subtype | posted_date ▲ | posted_year | posted_month | comment_start_date | comment_end_date | last_modified | fr_doc_num | open_for_comment | withdrawn | object_id |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| FDA-2020-D-1136-0075 | FDA | None FDA-2020-D-1136 | Guidance Documents Related to Coronavirus Disease 2019; Availability | Notice | Notice of Availability | 2021-10-06T04:00:00Z | 2021 | 10 | 2021-10-06T04:00:00Z | 2023-05-12T20:07:03Z | 2021-21798 | 0 | 0 | 0900006484dbc502 | |
| FDA-2020-D-1136-0074 | FDA | None FDA-2020-D-1136 | Development of Abbreviated New Drug Applications During the COVID-19 Pandemic – Questions and Answers; Guidance for Industry | Other | Guidance | 2021-09-08T04:00:00Z | 2021 | 9 | 2021-09-08T04:00:00Z | 2023-05-12T03:59:59Z | 2023-05-08T18:53:09Z | 0 | 0 | 0900006484d5f1ce | |
| FDA-2020-D-1136-0073 | FDA | None FDA-2020-D-1136 | Guidance Documents Related to Coronavirus Disease 2019; Availability | Notice | Notice of Availability | 2021-07-23T04:00:00Z | 2021 | 7 | 2021-07-23T04:00:00Z | 2023-05-12T20:06:35Z | 2021-15649 | 0 | 0 | 0900006484c097c2 | |
| FDA-2020-D-1136-0066 | FDA | None FDA-2020-D-1136 | Guidance: Documents Related to Coronavirus Disease 2019; Availability | Notice | Notice of Availability | 2021-05-27T04:00:00Z | 2021 | 5 | 2021-05-27T04:00:00Z | 2023-05-12T20:06:17Z | 2021-11217 | 0 | 0 | 0900006484b3ca2f | |
| FDA-2020-D-1136-0062 | FDA | None FDA-2020-D-1136 | Guidance Documents Related to Coronavirus Disease 2019; Availability | Notice | Notice of Availability | 2021-04-26T04:00:00Z | 2021 | 4 | 2021-04-26T04:00:00Z | 2024-11-06T23:46:13Z | 2021-08474 | 1 | 0 | 0900006484ab6bbf | |
| FDA-2020-D-1136-0057 | FDA | None FDA-2020-D-1136 | Remote Interactive Evaluations of Drug Manufacturing and Bioresearch Monitoring Facilities During the COVID-19 Public Health Emergency; Guidance for Industry | Other | Guidance | 2021-04-14T04:00:00Z | 2021 | 4 | 2021-04-14T04:00:00Z | 2024-11-06T23:47:11Z | 1 | 0 | 0900006484aa70cf | ||
| FDA-2020-D-1136-0056 | FDA | None FDA-2020-D-1136 | Development of Abbreviated New Drug Applications During the COVID-19 Pandemic – Questions and Answers - Guidance for Industry - April 2021 U.S. Department of Health and Human Services Food and Drug Administration Center for | Other | Guidance | 2021-04-07T04:00:00Z | 2021 | 4 | 2021-04-07T04:00:00Z | 2023-05-12T03:59:59Z | 2023-05-08T18:53:55Z | 0 | 0 | 0900006484a9f1b6 | |
| FDA-2020-D-1136-0051 | FDA | None FDA-2020-D-1136 | COVID-19 Container Closure System and Component Changes: Glass Vials and Stoppers Guidance for Industry March 2021 | Other | Guidance | 2021-03-05T05:00:00Z | 2021 | 3 | 2021-03-05T05:00:00Z | 2021-03-05T04:59:59Z | 2024-11-12T23:30:07Z | 1 | 0 | 0900006484a60779 | |
| FDA-2020-D-1136-0050 | FDA | None FDA-2020-D-1136 | Development of Monoclonal Antibody Products Targeting SARS-CoV-2, Including Addressing the Impact of Emerging Variants, During the COVID-19 Public Health Emergency - Guidance for Industry - February 2021 | Other | Guidance | 2021-02-22T05:00:00Z | 2021 | 2 | 2021-02-22T05:00:00Z | 2024-11-12T23:30:16Z | 1 | 0 | 0900006484a459a4 | ||
| FDA-2020-D-1136-0049 | FDA | None FDA-2020-D-1136 | Guidance Documents Related to Coronavirus Disease 2019; Availability | Notice | Notice of Availability | 2021-02-19T05:00:00Z | 2021 | 2 | 2021-02-19T05:00:00Z | 2024-11-12T23:27:55Z | 2021-03421 | 1 | 0 | 0900006484a42ed9 | |
| FDA-2020-D-1136-0047 | FDA | None FDA-2020-D-1136 | COVID-19: Potency Assay Considerations for Monoclonal Antibodies and Other Therapeutic Proteins Targeting SARS-CoV-2 Infectivity; Guidance for Industry | Other | Guidance | 2021-01-22T05:00:00Z | 2021 | 1 | 2021-01-22T05:00:00Z | 2024-11-06T23:44:17Z | 1 | 0 | 09000064849fccda | ||
| FDA-2020-D-1136-0046 | FDA | None FDA-2020-D-1136 | Protecting Participants in Bioequivalence Studies for Abbreviated New Drug Applications During the COVID-19 Public Health Emergency Guidance for Industry | Other | Guidance | 2021-01-19T05:00:00Z | 2021 | 1 | 2021-01-19T05:00:00Z | 2023-05-12T03:59:59Z | 2023-05-08T18:56:13Z | 0 | 0 | 09000064849f89c5 |
Advanced export
JSON shape: default, array, newline-delimited, object
CREATE TABLE documents (
id TEXT PRIMARY KEY,
agency_id TEXT,
docket_id TEXT REFERENCES dockets(id),
title TEXT,
document_type TEXT,
subtype TEXT,
posted_date TEXT,
posted_year INTEGER,
posted_month INTEGER,
comment_start_date TEXT,
comment_end_date TEXT,
last_modified TEXT,
fr_doc_num TEXT,
open_for_comment INTEGER,
withdrawn INTEGER,
object_id TEXT
);
CREATE INDEX idx_docs_agency ON documents(agency_id);
CREATE INDEX idx_docs_docket ON documents(docket_id);
CREATE INDEX idx_docs_date ON documents(posted_date);
CREATE INDEX idx_docs_year ON documents(posted_year);
CREATE INDEX idx_docs_type ON documents(document_type);
CREATE INDEX idx_docs_frnum ON documents(fr_doc_num);
CREATE INDEX idx_docs_comment_end ON documents(comment_end_date) WHERE comment_end_date IS NOT NULL AND withdrawn = 0;